BioLife Sciences Inc. (BLFE)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioLife Sciences Inc. (BLFE) with AI Score 48/100 (Weak). BioLife Sciences Inc. develops and distributes antibacterial products and non-contact human temperature screening technology. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026BioLife Sciences Inc. (BLFE) Healthcare & Pipeline Overview
BioLife Sciences Inc., operating in the healthcare sector, develops and distributes antibacterial and temperature screening products. The company focuses on disinfecting wipes, UV sterilization, electrostatic disinfection, and antimicrobial textiles. It caters to a market seeking enhanced hygiene and safety solutions, particularly in the wake of increased health awareness.
Investment Thesis
BioLife Sciences Inc. operates in the growing hygiene and infection control market. The company's focus on antibacterial products and temperature screening technology aligns with current health and safety concerns. However, negative profit and gross margins of -308.0% and -239.3% respectively, coupled with a negative P/E ratio, indicate financial challenges. The company's small size, with only 3 employees, and OTC listing introduce additional risks. Potential investors should carefully consider the company's financial performance and market position before investing. Growth catalysts include expanding product lines and market reach, but these must be balanced against the financial risks.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B reflects the company's small size and early stage.
- Negative P/E ratio indicates the company is not currently profitable.
- Profit Margin of -308.0% highlights significant financial losses.
- Gross Margin of -239.3% suggests challenges in product pricing and cost management.
- Beta of -2290.12 indicates high volatility and a negative correlation with the market.
Competitors & Peers
Strengths
- Focus on high-demand hygiene products
- Diverse product portfolio
- Potential for innovation in disinfection technologies
- Established distribution network
Weaknesses
- Small company size and limited resources
- Negative profit and gross margins
- OTC listing indicates higher risk
- Limited brand recognition
Catalysts
- Upcoming: Potential new partnerships to expand distribution channels.
- Ongoing: Increasing demand for hygiene products due to heightened health awareness.
- Ongoing: Development of new and innovative disinfection technologies.
Risks
- Potential: Intense competition from larger companies with greater resources.
- Potential: Fluctuations in raw material prices affecting profit margins.
- Potential: Changes in regulations and standards impacting product compliance.
- Ongoing: Negative profit and gross margins indicating financial instability.
- Ongoing: OTC listing indicating higher risk and lower liquidity.
Growth Opportunities
- Expansion of Product Line: BioLife Sciences can expand its product line to include more specialized disinfection solutions, such as hospital-grade disinfectants or advanced air purification systems. The global disinfection market is projected to reach $10.9 billion by 2027, offering a significant opportunity for growth. Timeline: 1-2 years.
- Geographic Expansion: The company can expand its geographic reach beyond Canada to target new markets in the United States and Europe. The increasing awareness of hygiene and infection control in these regions presents a favorable environment for growth. Timeline: 2-3 years.
- Strategic Partnerships: BioLife Sciences can form strategic partnerships with healthcare providers, schools, and businesses to integrate its products into their operations. These partnerships can provide a steady stream of revenue and increase brand awareness. Timeline: Ongoing.
- Development of Innovative Technologies: Investing in research and development to create innovative technologies, such as self-disinfecting surfaces or advanced temperature screening systems, can differentiate BioLife Sciences from its competitors and attract new customers. Timeline: 3-5 years.
- Focus on Antimicrobial Textiles: The antimicrobial textiles market is growing due to increasing demand for infection control in healthcare and other industries. BioLife Sciences can focus on developing and marketing antimicrobial textiles for various applications, such as medical apparel and bedding. Timeline: 2-3 years.
Opportunities
- Expansion into new markets
- Strategic partnerships with healthcare providers
- Development of innovative disinfection solutions
- Increased demand for hygiene products due to health concerns
Threats
- Competition from larger, more established companies
- Fluctuations in raw material prices
- Changes in regulations and standards
- Economic downturn affecting demand for hygiene products
Competitive Advantages
- Proprietary antibacterial technologies
- Established distribution network
- Strong relationships with key customers
- Focus on innovation and product development
About BLFE
BioLife Sciences Inc., incorporated in 2018 and based in Mississauga, Canada, operates within the medical instruments and supplies industry. The company specializes in developing, licensing, and distributing a range of antibacterial products and non-contact human temperature screening technology. Its product portfolio includes disinfecting wipes designed for surface sanitation, UV sterilization technology aimed at eliminating pathogens, electrostatic disinfection services for comprehensive area cleaning, and anti-microbial textiles intended to inhibit bacterial growth on fabrics. Additionally, BioLife Sciences offers touchless vending and marketplace products, catering to the growing demand for contactless solutions in retail and public spaces. The company's focus is on providing solutions that promote hygiene and safety across various environments. BioLife Sciences aims to capitalize on the increasing awareness and demand for infection control measures, positioning itself as a provider of innovative and effective hygiene solutions.
What They Do
- Develops antibacterial products
- Licenses antibacterial technologies
- Distributes antibacterial products
- Develops non-contact human temperature screening technology
- Offers disinfecting wipes
- Provides UV sterilization technology
- Offers electrostatic disinfection services
- Provides anti-microbial textiles
Business Model
- Develops and patents antibacterial technologies
- Licenses its technologies to other companies
- Manufactures and sells antibacterial products
- Provides disinfection services
Industry Context
BioLife Sciences Inc. operates in the medical instruments and supplies industry, which has seen increased demand for hygiene and infection control products. The market is competitive, with companies like BIOAF, BNYN, EMYSF, NVNO, and PHRX offering similar products. The industry is driven by increasing health awareness and stringent regulations. BioLife Sciences focuses on antibacterial products and temperature screening, aligning with current market trends. However, it faces competition from larger, more established players with greater resources and market reach.
Key Customers
- Hospitals and healthcare facilities
- Schools and educational institutions
- Businesses and offices
- Retail stores and supermarkets
- Government agencies
Financials
Chart & Info
BioLife Sciences Inc. (BLFE) stock price: Price data unavailable
Latest News
No recent news available for BLFE.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BLFE.
Price Targets
Wall Street price target analysis for BLFE.
MoonshotScore
What does this score mean?
The MoonshotScore rates BLFE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Justin De Four
CEO
Justin De Four is the CEO of BioLife Sciences Inc., managing a small team of 3 employees. Information regarding his prior experience and educational background is not available. As CEO, he is responsible for the overall strategic direction and operational management of the company, focusing on the development, licensing, and distribution of antibacterial products and temperature screening technology.
Track Record: Due to the limited information available, Justin De Four's specific achievements and strategic decisions as CEO of BioLife Sciences Inc. are unknown. The company's financial performance, as indicated by negative profit and gross margins, suggests significant challenges during his tenure.
BLFE OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BioLife Sciences Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like NYSE or NASDAQ due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Higher price volatility
- Potential for fraud or manipulation
- Lack of regulatory oversight
- Verify the company's registration and legal standing
- Review available financial statements and disclosures
- Assess the company's business model and competitive landscape
- Evaluate the management team and their track record
- Understand the risks associated with OTC investing
- Consult with a financial advisor
- Check for any regulatory actions or legal issues
- Company is registered and in good standing
- Company has a functional website and contact information
- Company has a clear business model and product offerings
- Company has been in operation for several years
- Company has a team of employees
BioLife Sciences Inc. Stock: Key Questions Answered
What does BioLife Sciences Inc. do?
BioLife Sciences Inc. specializes in developing, licensing, and distributing antibacterial products and non-contact human temperature screening technology. The company's product line includes disinfecting wipes, UV sterilization technology, electrostatic disinfection services, and anti-microbial textiles. These products cater to various sectors, including healthcare, education, and retail, addressing the increasing demand for hygiene and infection control solutions. The company aims to provide effective and innovative solutions to promote safer and healthier environments.
What do analysts say about BLFE stock?
As of 2026-03-17, there is no available analyst coverage or consensus on BioLife Sciences Inc. (BLFE) stock. The company's small market capitalization and OTC listing may contribute to the lack of analyst attention. Investors should conduct their own thorough research and due diligence before making any investment decisions. Key valuation metrics, such as P/E ratio and profit margins, indicate financial challenges that warrant careful consideration.
What are the main risks for BLFE?
BioLife Sciences Inc. faces several risks, including intense competition from larger, more established companies in the hygiene and infection control market. The company's negative profit and gross margins indicate financial instability and challenges in achieving profitability. As an OTC-listed stock, BLFE is subject to higher price volatility and lower liquidity. Changes in regulations and standards related to disinfection products could also impact the company's operations and financial performance. These risks should be carefully considered before investing in BLFE.
What are the key factors to evaluate for BLFE?
BioLife Sciences Inc. (BLFE) currently holds an AI score of 48/100, indicating low score. Key strength: Focus on high-demand hygiene products. Primary risk to monitor: Potential: Intense competition from larger companies with greater resources.. This is not financial advice.
How frequently does BLFE data refresh on this page?
BLFE prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BLFE's recent stock price performance?
Recent price movement in BioLife Sciences Inc. (BLFE) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on high-demand hygiene products. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BLFE overvalued or undervalued right now?
Determining whether BioLife Sciences Inc. (BLFE) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BLFE?
Before investing in BioLife Sciences Inc. (BLFE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing indicates higher risk and lower transparency.
- Lack of analyst coverage limits independent assessment.